JEFFREY J. KRAWS - Corporate Board Profile

Theriva Biologics, Inc.

Filing Date	Source Excerpt
2007-10-09	Mr. Kraws is Chief Executive Officer and co-founder of Crystal Research Associates, with a background in healthcare research and investment analysis.
2008-04-29	Mr. Kraws holds an MBA from Cornell University and a B.S. degree from State University of New York-Buffalo.
2009-11-20	Mr. Kraws holds an MBA from Cornell University and a B.S. degree from State University of New York-Buffalo. His experience is in healthcare research and investment analysis.
2010-09-29	He holds an MBA from Cornell University and a B.S. degree from State University of New York-Buffalo.
2012-01-04	Jeffrey J. Kraws (8) Includes 287,105 shares issuable upon exercise of options held by Mr. Kraws
2012-09-11	Mr. Kraws has a broad understanding of the operational, financial and strategic issues facing pharmaceutical companies. Through his services as the Companys Vice President of Business Development during 2006 and a part of 2007, he developed extensive knowledge of Synthetic Biologics business.
2013-09-24	Mr. Kraws has been a pharmaceutical analyst for over 22 years... He holds an M.B.A. from Cornell University and a B.S. degree from State University of New York-Buffalo.
2014-05-12	Mr. Kraws has been a director since January of 2006, and was appointed independent, non-executive Chairman of the Board in May 2012. Since 2003, Mr. Kraws has served Chief Executive Officer and co-founder of Crystal Research Associates... He holds an M.B.A. from Cornell University and a B.S. degree from State University of New York-Buffalo.
2015-04-13	Mr. Kraws has been a member of our Board of Directors since January of 2006... He holds an M.B.A. from Cornell University and a B.S. degree from State University of New York-Buffalo.
2016-07-06	Mr. Kraws has been a director since January of 2006, and was appointed independent, non-executive Chairman of the Board of Directors in May 2012. Since 2003, Mr. Kraws has served as Chief Executive Officer and co-founder of Crystal Research Associates, and since February 2012, he has served as partner and co-founder of TopHat Capital, LLC. Mr. Kraws is a Registered Representative at Terranova Capital Partners, Inc. since October 2014, a partner at Grannus Securities Pty Ltd. (an Australian based private equity fund) since November 2015 and a partner at Phoenix Holdings since November 2015. Well known and respected on Wall Street, Mr. Kraws has received some of the most prestigious awards in the industry. Among other awards, he was given a 5-Star Rating in 2001 by Zacks and was ranked the number one analyst among all pharmaceutical analysts for stock performance in 2001 by Starmine.com. Prior to founding Crystal Research Associates, Mr. Kraws served as co-president of The Investor Relations Group (IRG), a firm representing primarily under-followed, small-capitalization companies. Previously, Mr. Kraws served as a managing director of healthcare research for Ryan Beck & Co. and as director of research/senior pharmaceutical analyst and managing director at Gruntal & Co., LLC (prior to its merger with Ryan Beck & Company). Mr. Kraws served as managing director of the healthcare research group and senior pharmaceutical analyst at First Union Securities (formerly EVEREN Securities); as senior U.S. pharmaceutical analyst for the Swedish-Swiss conglomerate Asea Brown Boveri; and as managing director and president of the Brokerage/Investment Banking operation of ABB Aros Securities, Inc. He also served as senior pharmaceutical analyst at Nationsbanc Montgomery Securities, BT Alex Brown & Sons, and Buckingham Research. Mr. Kraws also has industry experience, having been responsible for competitive analysis within the treasury group at Bristol-Myers-Squibb Company. During 2006 through February of 2007, Mr. Kraws served as our Vice President of Business Development, on a part-time basis. Since December 2013, Mr. Kraws serves on the board of directors of Saleen Automotive, Inc. (OTC: SLNN). He holds an MBA from Cornell University and a BS degree from State University of New York Buffalo.
2017-07-18	Mr. Kraws has been a member of the Companys Board of Directors since January of 2006... Mr. Kraws has a broad understanding of the operational, financial and strategic issues facing pharmaceutical companies. Through his services as the Companys Vice President of Business Development during 2006 and a part of 2007, he developed extensive knowledge of the Companys business. Mr. Kraws brings a strong business background to the Company, having worked as a pharmaceutical analyst for over 25 years.
2018-08-14	Mr. Kraws brings a strong business background to Synthetic Biologics, having worked as a pharmaceutical analyst for over 22 years.
2019-07-15	Mr. Kraws brings a strong business background to us, having worked as a pharmaceutical analyst for over 22 years.
2020-08-04	Mr. Kraws has served as a pharmaceutical analyst for over 22 years and has a strong business background.
2021-08-16	Mr. Kraws brings a strong business background to us, having worked as a pharmaceutical analyst for over 22 years.
2022-08-16	Mr. Kraws brings a strong business background to us, having worked as a pharmaceutical analyst for over 22 years. Mr. Kraws brings to the Board of Directors significant strategic, business and financial experience related to the business and financial issues facing pharmaceutical companies.
2023-08-14	Mr. Kraws has a strong business background, having worked as a pharmaceutical analyst for over 22 years, with an MBA from Cornell University and a B.S. degree from State University of New York — Buffalo.
2024-09-30	Mr. Kraws has a strong business background, having worked as a pharmaceutical analyst for over 35 years, with an MBA from Cornell University and a B.S. degree from State University of New York — Buffalo.